AUTOFLEET/BLUEBIRD/ABEAM
22.4.2021 15:02:11 CEST | Business Wire | Press release
Bluebird Group (Bluebird), Indonesia’s leading taxi operator, has engaged with Autofleet and ABeam Consulting for a project to support its national fleet of over 23,000 vehicles with Autofleet’s Vehicle-as-a-Service platform. Bluebird and Autofleet have entered into a commercial agreement that is scheduled to roll out for vehicles operating in Jakarta and the surrounding area as soon as Q2 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005276/en/
By leveraging the Autofleet platform, Bluebird will be able to optimize its fleet’s vehicle placement, match and predict drivers based on demand forecasting to reduce empty rides, optimize allocation efficiency, allow for greater availability in traditionally under-served areas, reduce customer ETAs and improve overall customer experience. Autofleet is ingesting data from rides requested through the operator’s digital app and through traditional street hailing. These inputs are combined with real-time traffic data, weather forecasts, local events and other data points for increased demand prediction accuracy.
“The demand for mobility services has evolved, and it poses challenges that can only be solved by a combination of AI driven technology, and best in class operations. It is Bluebird’s value and commitment to deliver such customer-centric innovation through sustainable cooperation with our strategic partners, Autofleet and ABeam Consulting,” said Paul Soegianto, Chief Strategy Officer of PT Blue Bird Tbk.
In business for nearly 50 years, Bluebird serves millions of passengers every month. The fleet includes regular taxis (Bluebird & Pusaka), executive taxis (Silverbird), limousines and car rentals (Goldenbird), bus charters (Bigbird) and logistics (Birdkirim) among others. Autofleet’s platform will be integrated into the current dispatch infrastructure, supporting Bluebird, Silverbird and Birdkirim services in its first phase. In the longer term, the collaboration will inform Bluebird’s expanded activities in logistics and delivery services as well as exploration of new mobility infrastructure including electric vehicle (EV) charging.
“We are excited to partner with Bluebird, already a leader in mobility services in Southeast Asia, and apply the Autofleet platform to power current operations and prepare the business for future strategy and growth,” said Kobi Eisenberg, CEO at Autofleet. “Deploying Autofleet's platform will keep Bluebird at the cutting edge of the mobility industry, providing an outstanding customer experience, in a very competitive market.”
“ABeam Consulting is thrilled to support and expand Bluebird’s innovative services through AI and machine learning to increase operational efficiency,” said Tatsuya Kamoi, CEO at ABeam Consulting. “With our deep expertise in Mobility as a Service, we will support Bluebird’s operations and apply industry best practices to stay competitive with leading rideshare companies.”
In September 2020, Autofleet and ABeam Consulting entered a partnership to offer a comprehensive solution that supports Mobility as a Service (MaaS) projects end-to-end from the proposal stage to system implementation. Following projects in Japan and Cambodia, the engagement with Bluebird was secured through a year-long competitive proposal process and represents the largest commercial fleet management opportunity arising from the partnership to date.
About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/
.
About ABeam Consulting
ABeam Consulting Ltd., headquartered in Tokyo having 6,600 people serve more than 1,100 clients throughout Asia, in the Americas and Europe with its 28 offices since 1981, providing consulting services across various industries and with an expertise in digital transformation services that create strategic advantage, improve business processes, leverage technology innovation and enhance organizational performance.
Please contact and visit us under https://www.abeam.com/jp/en for more details.
About Bluebird
Established in 2001, PT Blue Bird Tbk (BIRD), is a public transportation company catering to passengers and providing other land transportation services. PT Blue Bird Tbk's 15 subsidiaries are found in 18 major cities around the country, namely Jakarta, Depok, Tangerang, Bekasi, Cilegon, Medan, Manado, Bandung, Palembang, Balikpapan, Padang, Pangkalpinang, Batam, Bali, Lombok, Semarang, Surabaya, Pekanbaru, Makassar, Solo and Yogyakarta.
Bluebird is committed to always provide safe, reliable, and comfortable transportation with easy accessibility for its customers. Companies extensive network covers more than 600 exclusive taxi outlets placed in malls, shopping centers and other strategic places. Serving millions of passengers every month.
Since going public on the Indonesia Stock Exchange in 2014, PT Blue Bird Tbk has gained status as a reliable and trustworthy transportation partner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005276/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom